Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL)

被引：0
|
作者：
Welt, A [1 ]
Fossa, A [1 ]
Blatter, J [1 ]
Buksmaui, S [1 ]
Seeber, S [1 ]
Nowrousian, MR [1 ]
机构：
[1] Univ Essen, Lilly Deutschland, W German Canc Ctr, Dept Med Oncol Canc Res, Bad Homburg, Germany
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
643
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [1] Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    Fosså, A
    Santoro, A
    Hiddemann, W
    Truemper, L
    Niederle, N
    Buksmaui, S
    Bonadonna, G
    Seeber, S
    Nowrousian, MR
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3786 - 3792
  • [2] Gemcitabine as single agent in the treatment of relapsed and refractory Hodgkin's and non-Hodgkin lymphoma.
    Jajeh, A
    Hadad, L
    Zalzaleh, G
    Ruestow, P
    BLOOD, 2003, 102 (11) : 285B - 285B
  • [3] Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma
    Dumontet, C
    Morschhauser, F
    Solal-Celigny, P
    Bouafia, F
    Bourgeois, E
    Thieblemont, C
    Leleu, X
    Hequet, O
    Salles, G
    Coiffier, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 772 - 778
  • [4] Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma
    Zlotnick, Maya
    Avigdor, Abraham
    Ribakovsky, Elena
    Nagler, Arnon
    Kedmi, Meirav
    ACTA HAEMATOLOGICA, 2019, 141 (02) : 84 - 90
  • [5] Gemcitabine as a single agent in the treatment of relapsed or refractory Hodgkin's and Non Hodgkin's lymphoma.
    Jajeh, A
    Hadad, L
    Godo, C
    Nukala, S
    BLOOD, 2001, 98 (11) : 242B - 243B
  • [6] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
  • [7] Treatment response to single agent sphingosomal vincristine in patients with relapsed and/or refractory diffuse aggressive non-Hodgkin's lymphoma (NHL): Subgroup analyses.
    Rodriguez, MA
    Winter, JN
    BLOOD, 2004, 104 (11) : 682A - 682A
  • [8] A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma
    Webb, MS
    Saltman, DL
    Connors, JM
    Goldie, JH
    LEUKEMIA & LYMPHOMA, 2002, 43 (05) : 975 - 982
  • [9] PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
    Roschewski, Mark
    Izumi, Raquel
    Hamdy, Ahmed
    Patel, Manish R.
    Arkenau, Hendrik-Tobias
    de Vos, Sven
    Reagan, Patrick M.
    Zinzani, Pier Luigi
    Davies, Andrew
    Pagel, John M.
    Vose, Julie M.
    Bitman, Bojena
    Brock, Graham
    Clark, Edwin
    Frigault, Melanie M.
    Ware, Joseph
    Yang, Buyue
    Wilson, Wyndham
    Staudt, Louis
    Flinn, Ian W.
    BLOOD, 2019, 134
  • [10] Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
    Davids, Matthew Steven
    Roberts, Andrew Warwick
    Seymour, John Francis
    Wierda, William G.
    Puvvada, Soham D.
    Gressick, Lori A.
    Alter, Debbie
    Zhou, Lang
    Kim, Su Young
    Verdugo, Maria
    Gerecitano, John F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345